Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF PANAMA SPECIFIC POLLEN ALLERGIES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
4.3 CURRENT PATENTS THAT CAN BE USED IN ALLOPATHIC MEDICINES IN MEXICO-
4.4 INVENTION PATENT-
4.5 COUNTRY LEVEL ANALYSIS
5 REGULATIONS
5.1 PANAMA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN PREVALENCE OF ALLERGIC DISORDER
6.1.2 WIDE RANGE OF PRODUCT PORTFOLIOS OFFERED BY MAJOR PLAYER
6.1.3 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION
6.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING
6.2 RESTRAINTS
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DRUGS
6.2.2 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS
6.3 OPPORTUNITIES
6.3.1 INCREASE IN THE ENVIRONMENTAL POLLUTION
6.3.2 AWARENESS OF THE USE OF OTC PRODUCTS
6.3.3 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING
6.4 CHALLENGES
6.4.1 INCREASE IN ABUSE POTENTIAL
6.4.2 INTELLECTUAL PROPERTY RIGHTS LAW
7 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 ANTIHISTAMINE
7.2.1 ANTIHISTAMINE, BY DRUG TYPE
7.2.2 LEVOCETIRIZINE
7.2.3 CETIRIZINE
7.2.4 LORATIDINE
7.2.5 DIPHENHYDRAMINE
7.2.6 CHLORPHENIRAMINE
7.2.7 FEXOFENADINE
7.3 CORTICOSTEROIDS
7.3.1 FLUTICASONE PROPIONATE
7.3.2 TRIAMCINOLONE/TRIAMCINOLONE ACETONOID
7.3.3 CROMOLYN SODIUM
7.3.4 OTHERS
7.4 DECONGESTANTS
7.4.1 DECONGESTANTS, BY DRUG TYPE
7.4.2 PSEUDOEPHEDRINE
7.4.3 PHENYLEPHRINE
7.4.4 OXYMETAZOLINE
7.4.5 OTHERS
7.5 ANTICHOLINERGICS
7.5.1 ANTICHOLINERGICS, BY DRUG TYPE
7.5.2 IPRATROPIUM BROMIDE
7.5.3 OTHERS
7.6 OTHERS
8 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMMUNO ASSAY ANALYZER
8.2.2 PRODUCTS, BY IMMUNOASSAY ANALYZER
8.3 RADIO IMMUNO ASSAY (RIA)
8.4 COUNTING IMMUNO ASSAY (CIA)
8.5 ENZYME LINKED IMMUNO-SORBENT ASSAYS (ELISA)
8.6 FLUOROIMMNOASSAY (FIA)
8.7 CHEMILUMINESCENCE ASSAY
8.7.1 LUMINOMETERS
8.8 REAGENTS AND KITS
8.9 OTHERS
9 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST
9.1 OVERVIEW
9.2 IN VIVO TEST
9.2.1 IN VIVO TEST, BY DIAGNOSTIC TEST
9.2.2 SKIN PRICK
9.2.2.1 SKIN PRICK, BY DIAGNOSTIC TEST
9.2.2.2 GREER PRICK
9.2.3 THE STELLAR POINT
9.2.4 PHAZET
9.2.5 BIFURCATED SMALLPOX VACCINATION TEST
9.2.6 23G INTRAVENOUS NEEDLE
9.2.7 OTHERS
9.2.8 PATCH TEST
9.2.9 INTRADERMAL TEST
9.3 IN VITRO TEST
9.3.1 IN VITRO TEST, BY DIAGNOSTIC TEST
9.3.2 SERUM SPECIFIC IGE ASSAY
9.3.3 TOTAL IGE ASSAY
9.3.4 BASOPHIL ACTIVATION TEST
10 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 DIAGNOSTICS LABORATORIES
10.4 ACADEMIC AND RESEARCH INSTITUTES
10.5 OTHERS
11 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
11.3.1 RETAIL SALES, BY TYPE
11.3.2 HOSPITAL PHARMACY
11.3.3 RETAIL PHARMACY
11.3.4 ONLINE PHARMACY
12 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: PANAMA SPECIFIC POLLEN ALLERGIES MARKET
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GLAXOSMITHKLINE PLC
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENTS
14.2 JOHNSON & JOHNSON SERVICES, INC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENTS
14.3 PERRIGO COMPANY PLC
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 SIEMENS HEALTHCARE GMBH
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENTS
14.5 THERMO FISHER SCIENTIFIC INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 BAYER AG
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ALCON INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 BIOMÉRIEUX, SA.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 CINFA LABORATORIES
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 CIRCASSIA
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENTS
14.12 LINCOLN DIAGNOSTICS, INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 MINARIS MEDICAL AMERICA, INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENTS
14.14 PRESTIGE CONSUMER HEALTHCARE INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 QUEST DIAGNOSTICS INCORPORATED
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 SANOFI
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 LEVOCETIRIZINE / MONTELUKAST- GLENMARK PHARMACEUTICALS LIMITED
TABLE 2 LEVOCETIRIZINE AND MONTELUKAST-
TABLE 3 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 4 PANAMA ANTIHISTAMINE DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 5 PANAMA ANTIHISTAMINE DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)
TABLE 6 PANAMA CORTICOSTEROIDS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 7 PANAMA CORTICOSTEROID DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)
TABLE 8 PANAMA DECONGESTANTS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 9 PANAMA DECONGESTANTS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)
TABLE 10 PANAMA ANTICHOLINERGIC DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 11 PANAMA ANTICHOLINERGICS DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (UNITS)
TABLE 12 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 13 PANAMA INSTRUMENTS IN SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 14 PANAMA IMMUNO ASSAY ANALYZER IN SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 15 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2020-2029 (USD MILLION)
TABLE 16 PANAMA IN VIVO TEST IN SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2020-2029 (USD MILLION)
TABLE 17 PANAMA ANTIHISTAMINE DRUG TYPE IN SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 18 PANAMA IN VITRO TEST IN SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2020-2029 (USD MILLION)
TABLE 19 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 20 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 21 PANAMA RETAIL SALES IN SPECIFIC POLLEN ALLERGIES MARKET, BY TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: SEGMENTATION
FIGURE 2 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: DATA TRIANGULATION
FIGURE 3 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: DROC ANALYSIS
FIGURE 4 PANAMA SPECIFIC POLLEN ALLERGIES MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 PANAMA SPECIFIC POLLEN ALLERGIES MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: SEGMENTATION
FIGURE 11 THE HIGH PREVALENCE OF ALLERGIC RESPONSE AND INCREASING APPROVAL OF NEW PRODUCT IS EXPECTED TO DRIVE THE PANAMA SPECIFIC POLLEN ALLERGIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 DRUG TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE PANAMA SPECIFIC POLLEN ALLERGIES MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF PANAMA SPECIFIC POLLEN ALLERGIES MARKET
FIGURE 14 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE, 2021
FIGURE 15 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS, 2021
FIGURE 16 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST, 2021
FIGURE 17 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY END USER, 2021
FIGURE 18 PANAMA SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL, 2021
FIGURE 19 PANAMA SPECIFIC POLLEN ALLERGIES MARKET: COMPANY SHARE 2021 (%)
